Arrowstreet Capital
CDTX

Arrowstreet Capital’s Cidara Therapeutics CDTX Stock Holding History

Arrowstreet Capital’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-820
Closed -$47K – 2305
2020
Q3 		$47K Buy
+820
New +$57.9K ﹤0.01% 2284

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital's CDTX Position: Q4 2020 in Review

Arrowstreet Capital sold out of Cidara Therapeutics (CDTX) in Q4 2020, closing a stake of 820 shares — an estimated $47K sold.

Arrowstreet Capital first reported a position in CDTX in Q3 2020 and held it in 1 quarter. The position peaked at $47K in Q3 2020. 63 funds tracked by Wall St. Rank hold CDTX as of Q4 2020.

  • Arrowstreet Capital reported no remaining Cidara Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 820 Cidara Therapeutics shares in Q4 2020, an estimated $47K.
  • Arrowstreet Capital first reported a position in Cidara Therapeutics in Q3 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Cidara Therapeutics position peaked at $47K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.